help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pagotto, U.
Right arrow Articles by Stalla, G. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pagotto, U.
Right arrow Articles by Stalla, G. K.
Endocrinology Vol. 140, No. 2 987-996
Copyright © 1999 by The Endocrine Society


ARTICLES

Inhibition of Zac1, a New Gene Differentially Expressed in the Anterior Pituitary, Increases Cell Proliferation1

Uberto Pagotto2, Thomas Arzberger2, Elisabetta Ciani, Franck Lezoualc’h, Catia Pilon, Laurent Journot, Dietmar Spengler and Günter K. Stalla

Max Planck Institute of Psychiatry (U.P., E.C., F.L., D.S., G.K.S.), 80804 Munich; and the Departments of Neurology, Technical University of Munich (T.A.), 81675 Munich, Germany; Centre National de la Recherche Scientifique (L.J., D.S.), 34094 Montpellier Cedex 05, France; and the Institute of Semeiotica Medica, University of Padua (C.P.), Padua, Italy

Address all correspondence and requests for reprints to: Uberto Pagotto, M.D., Department of Endocrinology, Max Planck Institute of Psychiatry, Kraepelinstrasse 10, 80804 Munich, Germany. E-mail: pagotto{at}mpipsykl.mpg.de


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Zac1 is a new zinc finger protein that concomitantly controls apoptosis and cell cycle arrest through separate pathways. The mouse Zac1 gene is mainly expressed in the pituitary gland and in different brain areas. In this study regional and cellular expression of Zac1 in the pituitary gland was determined by in situ hybridization. Zac1 messenger RNA was abundantly expressed in the anterior pituitary lobe compared with that in the intermediate and posterior lobes. Zac1 transcripts were found in all hormone-secreting cell types, with the highest levels in GH- and PRL-producing cells.

To investigate the impact of Zac1 in pituitary cell proliferation, we ablated the endogenous Zac1 gene by antisense treatment in two murine cell types, AtT-20 and TtT/GF, that are representative of granular and agranular cell lineages, respectively. The decline in Zac1 protein levels under antisense treatment was accompanied by increased DNA synthesis in clonal corticotroph and folliculo-stellate cells, as demonstrated by enhanced [3H]thymidine incorporation (36% and 50%, respectively). Antisense oligonucleotides against Zac1 controlled cell proliferation in a dose-dependent way, and mutagenized antisense oligonucleotides were inert. Conclusively, our data provide the first evidence of a role for Zac1 in pituitary growth control.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
DUE TO ITS mitotic activity (1), the anterior pituitary can be considered to be an expanding cell population (2), whose homeostasis reflects a fine-tuned balance among cell division, cell cycle arrest, differentiation, and apoptosis (3). On the average, a young adult male rat anterior pituitary cell either dies or divides once every 60–70 days, resulting in an overall pituitary parenchymal cell turnover rate of 1.58%/day (3). These functions are tightly regulated by a complex interaction between hypothalamic hypophysiotropic peptides (4) and growth factors (5), which are relevant to the mechanisms responsible for both pituitary tumor initiation and progression (for review, see Ref. 6). With significant frequency, pituitary cells undergo unbalanced proliferation (7), resulting in tumors that are usually benign, with a random occurrence in 10–23% of autopsy examinations (8, 9). The common point of view is that a mutual interplay of intrapituitary and extrapituitary pathogenetic factors drives tumoral development and progression. Concerning intrinsic pituitary defects, a number of recent studies have addressed the alterations of genes that suppress cell proliferation by acting on the cell cycle machinery. Among these, the retinoblastoma and p27 genes were anticipated to play a critical role in pituitary tumorigenesis based on the high occurrence of tumors arising from the intermediate lobe of the pituitary gland of null-mutant mice (10, 11, 12). Yet studies aimed to identify deletions or mutations leading to an inactivation of these genes in pituitary tumor specimens remain controversial, giving no definitive answer to date (for review, see Refs. 6, 13).

We recently reported the isolation of a new gene from a mouse corticotroph library designated Zac1, which encodes a seven-zinc finger protein inducing concomitantly apoptosis and cell cycle arrest (14). Expression of Zac1 prevented the proliferation of tumor cells as measured by colony formation, growth rate, and cloning in soft agar, and precluded tumor formation in nude mice (14). Furthermore, Zac1 was demonstrated to induce the expression of pituitary adenylate cyclase-activating polypeptide (PACAP) type 1 receptor (PR1) in different cell lines (15).

Interestingly, Hamilton and colleagues independently identified a rat complementary DNA closely related to mouse Zac1 (90% homology) through its loss of expression in a rat model of epithelial ovary transformation. Accordingly, they named this gene LOT1 for "lost on transformation" (16). Moreover, the same researchers found a marked reduction of expression of the human LOT1 gene (85% homology to mouse Zac1) in human ovary cancer cell lines (17). Together, the functional properties of Zac1 and the loss of expression of its human counterpart suggest a growth-restraining function in differentiation and tumorigenesis.

To gain further insight into the role of Zac1 in the pituitary gland, we determined the regional and cellular expression pattern of Zac1 in the mouse pituitary using in situ hybridization (ISH). To identify the anterior pituitary cell type(s) that contains Zac1 transcripts, ISH was combined with immunohistochemistry (IHC) using antisera against anterior pituitary cell markers. Moreover, we investigated the effect of Zac1 on growth by inhibiting the endogenous Zac1 gene expression using antisense (AS) oligodeoxynucleotides (ODNs) in two murine clonal cells, representative of hormone-secreting or nonsecreting cells, corticotroph (AtT-20) and folliculo-stellate (FS)(TtT/GF) cells, respectively.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Animals and tissue preparation
Adult (30–35 g) male B6C3F1 mice (Charles River, Sulzfeld, Germany) were decapitated, and the whole pituitary glands were immediately removed. The glands were fixed for 48 h in 4% phosphate-buffered paraformaldehyde for ISH experiments.

ISH
ISH was performed as previously described with minor modifications (18). In brief, 8-µm pituitary sections were cut in a cryostat, thaw-mounted onto sterile slides, postfixed in 4% paraformaldehyde, and stored in 96% ethanol until use. Five different ODNs (Pharmacia Biotech Benelux, Roosendaal, The Netherlands) were selected for their ability to hybridize to the zinc finger, the linker, the proline repeat, and the carboxyl-terminal region of mouse Zac1-coding sequence (EMBL accession no. X95503) (14) and were named accordingly to their location: ZF [nucleotides (nt) 238–282], L (nt 769–813), PR (nt 895–939), CT1 (nt 1156–1200), and CT2 (nt 1311–1355). The sequences are presented in Table 1Go. ODNs were 3'-end labeled with [{alpha}-33P]deoxy-ATP (NEN, Cologne, Germany) by terminal transferase (Boehringer Mannheim, Mannheim, Germany). After hybridization and washing, sections were exposed to Betamax Hyperfilms (Amersham International, Aylesbury, UK) for 14 days or dipped in Ilford K5 photoemulsion (Ilford, Dreieich, Germany) and developed after 28 days. For a negative control, a 100-fold excess of nonlabeled ODNs was added to the radioactive probe.


View this table:
[in this window]
[in a new window]
 
Table 1. Zac1 oligonucleotides for in situ hybridization and antisense experiments

 
Colocalization studies
IHC was performed as described in our previous reports (19), and combined ISH and IHC were performed as previously reported (20). The following antisera were used: monkey antiserum against rat GH (diluted 1:1000); rabbit antisera against rat FSHß (1:600), LH (1:600), TSHß (1:600), and ACTH (1:700; all donated by the National Hormone and Pituitary Program, NIDDK, Bethesda, MD); and rabbit antisera against mouse PRL (1:600; gift from Dr. F. Talamantes, University of California, Santa Cruz, CA) and against bovine S-100 (1:300; Biogenesis Ltd., Poole, UK), a marker for FS cells. As secondary antibodies, biotinylated goat antirabbit IgGs (1:300; Vector Laboratories, Inc., Burlingame, CA) or biotinylated goat antimonkey IgGs (1:700; gift from Dr. G. L. Ferri, University of Cagliari, Cagliari, Italy) were used. The specificity of the antisera against pituitary hormones was examined by preabsorption with the respective antigens. For negative controls, either primary antisera were omitted, or sections were incubated with normal rabbit or monkey serum (1:100) instead of antisera.

Quantification of hybridization signals at the cellular level in immunohistochemically identified pituitary cells
Slide preparations of three different colocalization experiments for GH, PRL, ACTH, LH, TSH, FSH, and S-100 in mouse pituitary were selected for signal quantification, and 10 different areas for each experiment were scanned with a ProgRes 3012 Mikroscancamera (Imagine, Munich, Germany) connected to a DMRD Leica Corp. microscope (Leica Corp., Bensheim, Germany) in a standardized manner at a resolution of 300 pixels/in. For quantification of hybridization signals, the Optimas 5.2 computer program (Optimas Corp., East Aspen, MT) was used. A threshold range for gray values was set in brightfield images recognizing only immunopositive structures, and their total area was automatically determined by the program. This was followed by a determination of the total area of silver grains inside these structures after overlaying the corresponding darkfield image and setting a threshold range recognizing only silver grains. For measurements of nonspecific background, noncellular areas were manually outlined with the cursor, and the total area of silver grains inside was determined. Two different ratios were calculated: ratio 1, the sum of the total areas of silver grains inside areas of immunostained structures (obtained in all images of the same experiment for each kind of immunostaining)/the sum of the total areas of immunostained or cellular structures; and ratio 2, the sum of the total areas of silver grains inside selected areas for background measurements/the sum of selected areas for background measurements. Finally, ratio 2 was subtracted from ratio 1 to obtain background-free values.

Cell cultures
Cell culture materials and reagents were obtained from Life Technologies (Karlsruhe, Germany), Falcon (Heidelberg, Germany), Nunc (Wiesbaden, Germany), Seromed (Berlin, Germany), Flow (Meckenheim, Germany), and Sigma Chemical Co. (St. Louis, MO). Stock cultures of AtT-20 and TtT/GF cells were grown at 37 C and 5% CO2 in DMEM (pH 7.3) supplemented with 10% (AtT-20) or 2% FCS (TtT/GF), 2 mM glutamine, and antibiotics. Cells were seeded in 48-well plates for AS experiments, in double slides for fluorescence experiments, or in 10-cm2 petri dishes for protein extraction. All experiments were performed on cells in the midlog phase.

ODNs and transfection
The translation start region or its immediate vicinity of Zac1 messenger RNA (mRNA) were selected as a target to block Zac1 protein translation. Three 20-mer AS ODNs (AS1, AS2, AS3) and three 20-mer mutagenized (MUT) sequences (MUT1, MUT2, MUT3; phosphorothioates at 3'- and 5'-terminals) with four mismatches maintaining the A, T, G, and C contents were purchased from MWG-Biotech (Ebersberg, Germany). Their sequences are shown in Table 1Go. To visualize the ODN incorporation and the intracellular distribution, the AS ODNs were 3'-labeled with rhodamine (MWG-Biotech).

AtT-20 and TtT/GF cells were transfected by a recently reported procedure using polyethylenimine (PEI) (21). ODNs at various concentrations and PEI at 8 equivalents were first diluted in 150 mM NaCl and complexed by gently mixing the two solutions. After 10 min, the transfectant solution mixture was diluted in 450 µl DMEM without serum and applied to the cells for 2 h. Finally, the cells were rinsed and cultured with fresh DMEM supplemented with 10% (AtT-20) or 2% (TtT/GF) FCS for the studies described below. Control AtT-20 and TtT/GF were treated as described above with the ODNs omitted.

Determination of [3H]thymidine incorporation
[3H]Thymidine incorporation was determined as previously described with minor modifications (18). Sixteen hours after transfection, the cells were incubated with 0.5 µCi/ml [3H]thymidine for 3 h. The medium was then removed, and the cells were precipitated with ice-cold 10% trichloroacetic acid (1 h; 4 C) and washed with cold PBS. Finally, the DNA was hydrolyzed overnight with 0.5 M NaOH-0.1% Triton X-100, and the radioactivity was determined with a liquid scintillation counter.

Bromodeoxyuridine (BrdU) staining
BrdU staining was performed as previously described with minor modifications (18) according to the instructions of the manufacturer (5-Bromo-2'-Deoxy-Uridine Labeling and Detection Kit II, Boehringer Mannheim). In brief, 16 h after transfection, the cells were incubated with 10 µM BrdU for 45 min, medium was removed, and cells were fixed in 70% ethanol for 30 min at -20 C. Mouse mAb anti-BrdU (1:10) was applied, followed by antimouse Ig-alkaline phosphatase (1:10).

Western blotting analysis
Western blotting was performed as described previously (14) with minor modifications. In brief, AtT-20 and TtT/GF cells were harvested in Tris-EDTA with 0.001% protease inhibitor cocktail (Sigma Chemical Co.) and 1 mM dithiothreitol and disaggregated by passing through a 21-gauge needle. Total cellular extracts (30 µg) were resolved on 8% SDS-PAGE gels and transferred to nitrocellulose membrane. The blot was blocked in Tris-buffered saline with 4% BSA and 0.05% Tween-20 for 1 h and incubated with purified rabbit polyclonal against Zac1 (1:5000) (14) or rabbit polyclonal against actin (1:200; Sigma Chemical Co.) for quantification overnight at 4 C, followed by the second antibody conjugated to horseradish peroxidase. Detection was performed using the BM Chemiluminescence Western blotting kit (Boehringer Mannheim).

Statistics
Statistics for growth studies of AtT-20 and TtT/GF were performed by ANOVA in combination with Scheffe’s test. Data are shown as the mean ± SD. Each experimental condition was performed in six replicates.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Regional and cellular Zac1 mRNA expression in the pituitary gland
To evaluate Zac1 gene expression in the different lobes of the mouse pituitary gland, transverse sections were first hybridized with the ZF ODN probe.

At the regional level, very strong hybridization signals for Zac1 mRNA were found in the anterior pituitary lobe, strong signals were found in the intermediate lobe, and weak signals were seen in the posterior lobe, as shown in Fig. 1aGo. Identical results were obtained with ODN probes complementary to other parts of the coding region of Zac1 (L, PR, C1, and C2), indicating that a single class of transcripts corresponding to the mouse Zac1 gene were detected (data not shown). Furthermore, the strong signals observed in the anterior lobe were completely suppressed by competition with a 100-fold excess of the corresponding unlabeled ODN (Fig. 1bGo), emphasizing the specificity of the signal.



View larger version (152K):
[in this window]
[in a new window]
 
Figure 1. a–f, Zac1 mRNA expression in mouse pituitary lobes at a regional (a and b) and cellular level (c-f). a and b, Autoradiographs. Betamax Hyperfilms. c–f, Histoautoradiographs. a, Hybridization signals for Zac1 mRNA are abundant in the anterior pituitary lobe (al), distinct in the intermediate lobe (il), and weak in the posterior lobe (pl). b, Only nonspecific background remains in the adjacent section in the presence of a 100-fold excess of unlabeled probe. c, Nearly all cells of the anterior lobe contain Zac1 transcripts (silver grains), but the number of silver grains per cells varies, indicating different cellular mRNA levels. d, The hybridization signals are suppressed in the corresponding negative control. e, In an area of the intermediate lobe juxtaposed to the posterior lobe, the majority of cells express Zac1 mRNA. mRNA levels range from high (indicated by double arrows) to low (indicated by single arrows). f, Only weak signals are present in a few pituicytes of pl (examples are indicated by arrows). a and b, x23. c–f, x520.

 
At the cellular level, only a few cells without hybridization signals for Zac1 mRNA (silver grains in histoautoradiographs) were found in the anterior lobe (Fig. 1cGo). The number of silver grains per cell varied, indicating that the cells differed in their content of Zac1 mRNA (Fig. 1cGo). This heterogeneity in Zac1 gene expression was consistently observed in different tissue preparations and thus was unrelated to variations in the preparation process. This finding was not confined to the anterior lobe, but was also encountered in the intermediate lobe, where the majority of cells contained Zac1 transcripts (Fig. 1eGo).

In the posterior lobe only scattered pituicytes expressed Zac1 mRNA at low levels (Fig. 1fGo).

Colocalization of Zac1 mRNA and immunohistochemical markers for the anterior pituitary cells
To identify pituitary cell populations expressing Zac1 mRNA, we combined ISH for Zac1 with IHC for anterior pituitary hormones and S-100.

All anterior pituitary cell types were found to contain Zac1 transcripts but at varying levels. Hybridization signals were most intense in GH-producing (Fig. 2aGo) and PRL-producing (Fig. 2bGo) cells; lower in LH-positive (Fig. 2cGo), TSH-positive (Fig. 2dGo), and ACTH-positive (Fig. 2fGo) cells; and lowest in FSH-producing cells (Fig. 2eGo). After GH- and PRL-secreting cells, FS cells showed the highest hybridization signals for Zac1 transcripts (Fig. 2gGo). The values of the quantified Zac1 mRNA levels in each pituitary cell type are shown in Fig. 3Go and are representative of one experiment. Similar results were obtained in two other independent experiments.



View larger version (115K):
[in this window]
[in a new window]
 
Figure 2. a–g, Zac1 mRNA expression in GH-producing (a), PRL-producing (b), LH-producing (c), TSH-producing (d), FSH-producing (e), ACTH-producing (f), and S-100-positive (g) cells of the mouse anterior pituitary lobe. Histoautoradiographs. a–g, Different intensities of hybridization signals for Zac1 mRNA (silver grains) are observed in different immunohistochemically identified (dark brown) types of anterior pituitary lobe cells. The highest mRNA levels are detected in GH-producing (a) and PRL-producing (b) cells. In LH-positive (c), TSH-positive (d), and ACTH-positive (f) cells, mRNA levels are lower. Only weak hybridization signals are observed in FSH-producing cells (e). Also folliculo-stellate cells expressing S-100 show Zac1 transcripts (g). Magnification, x640.

 


View larger version (15K):
[in this window]
[in a new window]
 
Figure 3. Quantification of hybridization signals for Zac1 mRNA in immunohistochemically identified pituitary cells. Background free values are given as ratio 1 - ratio 2, calculated as described in Materials and Methods. GH- and PRL-producing cells exhibited the major amount of hybridization signals for Zac1 mRNA.

 
AS transfection and effect on proliferation in pituitary cell lines
We previously demonstrated that ectopic expression of Zac1 induces G1 cell cycle arrest in both LLC-PK1 and SaOs-2 cells. To substantiate this finding in an endogenous model we determined the effects of reducing Zac1 expression by AS treatment. We paid particular attention to the design of the AS ODN and the corresponding controls (Table 1Go). Briefly, three AS ODNs (AS1 to AS3) were used to investigate whether the biological effect is reproducible with more than one AS ODN. Accordingly, the effects of three different AS ODNs on the proliferation of pituitary cells in midlog phase were compared with the effects of three MUT ODN sequences (Table 1Go). As the outcome of a transient knockout experiment will depend on the numbers of cells that take up the AS ODN, we first tested the efficiency of our transfection method. For this reason we used rhodamine-labeled ODNs and examined their distribution in cultures exposed either to ODN alone or to ODN/PEI complexes. With the latter condition in AtT-20 and TtT/GF cells, we observed by fluorescence microscopy detectable signals in the majority of the cells (Fig. 4Go), in contrast to a complete absence of signal in cultures exposed solely to rhodamine-coupled ODNs (data not shown). Counting at least 10 fields in each of 3 different experiments, the highest transfection efficiency (70%) was achieved for both cellular lineages when 1 µM ODN was applied. Next, we tested the effects of all 3 AS on [3H]thymidine incorporation in AtT-20 and TtT/GF cells. We found that AS1 at a concentration of 1 µM ODN increased [3H]thymidine incorporation by 36% in AtT-20 and by 50% in TtT/GF (Fig. 5Go, A and C), whereas AS2 caused increases of 20% and 28%, respectively (Fig. 5Go, B and D), compared with the MUT ODNs and the control. An increase in thymidine uptake was also observed with 1 µM AS3 in both AtT-20 and TtT/GF, but was not significant (data not shown). We then performed a dose-response study using AS1 ODN concentrations between 0.3–1 µM with AtT-20 and between 0.3–1.5 µM with TtT/GF. AS1 ODN maximally stimulated proliferation at 1.0 µM in AtT-20 and at 1.5 µM in TtT/GF cells. However, even at lower concentrations, a significant effect was detectable. No significant effect on proliferation was observed for MUT1 ODN at any of the concentrations used (Fig. 6Go). BrdU immunohistochemical staining of AtT-20 and TtT/GF cells confirmed that the number of the nuclei incorporating BrdU was increased after treatment with AS1 (1.0 µM) compared with MUT1 (1.0 µM) or PEI alone (Fig. 7Go). Light microscopic inspection of the cells treated with the above-mentioned AS ODN concentrations, either immediately after transfection or 16 h before thymidine application, gave no evidence of changes in cell morphology or reduced viability. Only at ODN concentrations higher than 1.0 µM for AtT-20 and 1.5 µM for TtT/GF was a toxic effect noticed, and this could be attributed to the transfectant vector PEI, as a similar decrease in viability was seen with the equivalent PEI in controls. To examine whether the increased DNA synthesis under AS ODNs was actually accompanied by decreases in the levels of Zac1 protein in AtT-20 and TtT/GF, cells were treated for 2 h with ODN/PEI, and cell extracts were harvested for immunoblot analysis after 16 h. As shown in Fig. 8Go, a clear reduction of the signal for Zac1 protein was obtained after AS1 ODN treatment compared to that after MUT1 ODN treatment. Densitometric measurements revealed a 62% decrease for TtT/GF and 27% for AtT-20, indicating that the observed decline in Zac1 protein levels correlates with the increase in DNA synthesis under the same condition. The incomplete suppression of the signal after AS ODN treatment was in accordance with our observation that the majority, but not all, of the cells were transfected.



View larger version (99K):
[in this window]
[in a new window]
 
Figure 4. a–d, Intracellular distribution of rhodamine-labeled ODNs in AtT-20 (a and b) and TtT/GF cells (c and d). a and c, Phase contrast microscopy. b and d, Rhodamine fluorescence microscopy. AtT-20 and TtT/GF were seeded in double slide flasks at a concentration of 20,000 cells/well. Rhodamine-ODN/PEI complexes were applied at a concentration of 1 µM for 2 h. Rhodamine-labeled ODNs were incorporated into many of the AtT-20 and TtT/GF cells. Corresponding transfected cells are marked by single headed arrows; nontransfected cells are indicated by double headed arrows pointing in the same direction.

 


View larger version (43K):
[in this window]
[in a new window]
 
Figure 5. A–D, Effects of ODNs (AS1 and AS2) directed against Zac1 on DNA synthesis in AtT-20 and TtT/GF cells. AtT-20 (A and B) and TtT/GF (C and D) were cultured in complete DMEM with 10% or 2% FCS, respectively, for 3 days in 48-well plates at a concentration of 20,000 cells/0.5 ml, then washed and cultured for 2 h in DMEM supplemented with AS1 (A and C) and AS2 ODNs (B and D; 1 µM, complexed with PEI for AS and MUT, with PEI alone for control). After replacing with fresh medium containing FCS for 16 h, they were treated with [3H]thymidine for the remaining 3 h. [3H]Thymidine incorporation was determined as described in Materials and Methods. Means ± SD are given (n = 6). The experiments were repeated three times for each AS ODN. Representative results from one experiment are shown. *, P < 0.01; **, P < 0.001.

 


View larger version (18K):
[in this window]
[in a new window]
 
Figure 6. A and B, Stimulation of DNA synthesis in AtT-20 and TtT/GF cells by increasing concentrations of AS1 ODN. Cells were treated as described in Fig. 5Go. AS1 and MUT1 (complexed with PEI) were added at concentration ranging from 0.3–1.0 µM for AtT-20 (A) and from 0.3–1.5 µM for TtT/GF (B). • and {blacksquare}, AS1; {circ} and {square}, MUT1. The mean ± SD are given (n = 6). The experiments were repeated three times. Representative results from one experiment are shown. *, P < 0.05; **, P < 0.01; ***, P < 0.001.

 


View larger version (132K):
[in this window]
[in a new window]
 
Figure 7. a–f, AtT-20 and TtT/GF cells in culture undergoing synthesis after AS1 ODN treatment immunohistochemically identified by BrdU staining. Cells were treated as described in Fig. 5Go and transfected with AS1 (a and b), MUT1 (c and d), and control (e and f). 1 µM ODN complexed with PEI for AS1 and MUT1, only PEI for control. The number of the nuclei incorporating BrdU is increased in AS1-treated AtT-20 and TtT/GF cells in comparison to cells treated with MUT1 or PEI alone (control).

 


View larger version (31K):
[in this window]
[in a new window]
 
Figure 8. Inhibition of Zac1 protein expression in AtT-20 and TtT/GF cells by AS1 ODN. AtT-20 and TtT/GF cells were seeded in 10-cm2 petri dishes at a concentration of 500,000 cells/petri dish in DMEM with the ingredients indicated in Materials and Methods. After 48 h, the cells were treated with ODNs (AS1 and MUT1) complexed with PEI at a concentration of 1 µM for 2 h; then the cells were washed with fresh medium and harvested for Zac1 and actin protein extraction after 16 h. Protein extracts were processed as indicated in Materials and Methods.

 
In summary, Zac1 antisense treatment led to increased DNA synthesis in the pituitary cell lines tested, which was specific in terms of the absence of any stimulatory effect for the mutagenized antisense form and showed a clear dose dependency, an absence of toxicity at the doses used, and a concomitant decrease in the target protein.


    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
In this study we documented for the first time the intracellular localization of Zac1 mRNA in the pituitary, and we gave new evidence for the role of Zac1 in the control of pituitary cell proliferation. Combining ISH with IHC, we observed that all hormone-producing cell types of the anterior pituitary displayed Zac1 mRNA to varying degrees. Signals were highest in GH- and PRL-; lower in LH-, TSH-, and ACTH-; and weakest in FSH-producing cells. Notably was the expression of Zac1 mRNA in FS cells.

In the past, the mitotic activity in the adult anterior pituitary gland has been thought to be low (22). This view has faced increasing challenge and has been highlighted in the recent work by Levy and colleagues (3), who concluded that, on the average, a pituitary cell enters mitosis (or apoptosis) once every 60–70 days, yielding a significant cellular turnover (>1.5%/day). Age, sex, and circadian differences (23, 24, 25) as well as exposure to hormones (26, 27, 28) have been reported to regulate the number of mitotic cells in anterior pituitary. Therefore, heterogeneous Zac1 mRNA levels in the anterior pituitary gland could reflect differences in the mitotic activity of individual subsets of cells.

In previous reports we have shown that Zac1 is able to induce the expression of PR1 in a panel of cell lines of various origin (15). Several peptidergic factors of hypothalamic origin are known to take part in the control of hormonal production and pituitary gland growth. Among these, PACAP acts as a hypophysiotropic factor, mainly through an activation of PR1 (for review, see Refs. 29, 30). Several studies demonstrated high expression of PR1 mRNA and protein in the anterior and intermediate lobes, in contrast to a very low expression in the posterior pituitary lobe (14, 31, 32). Moreover, using biotinylated ligands it was demonstrated that PACAP binds to all types of hormone-producing cells of the anterior pituitary gland, with the highest percentage binding to GH- and PRL-producing cells and the lowest to FSH-secreting cells (33). Our description of the regional and quantitative cellular distribution of Zac1 mRNA in the pituitary gland tightly correlates with the distribution of PR1 observed by others (14, 31, 32, 33). Thus, one may speculate that at the pituitary level Zac1 could take part in the mechanisms of action commonly attributed to PACAP, such as the ability to modify the paracrine milieu and to influence cell growth and differentiation, through the activation of PR1.

Together with the corticotroph lineage AtT-20, in which Zac1 was isolated, we found a constitutive expression of Zac1 protein in TtT/GF cells. This pituitary FS-like cell line represents a unique model to study the possible multifunctional roles of FS in regulating the extracellular environment of the anterior pituitary and in releasing paracrine factors that regulate the activity of other cell types (34).

In our previous report we demonstrated that an ectopic expression of Zac1 induces apoptosis and G1 arrest, resulting in a severe growth inhibition (14). As these studies relied on an enforced expression in a heterologous model, it remained of obvious interest to substantiate these findings in a model of physiological relevance. Based on the G1 arrest function of Zac1, we reasoned that the regulatory role of Zac1 on the cell cycle will be unmasked by an ablation of the endogenous gene, and we predicted an increased entry into the S phase under this condition. To this aim we used AS ODNs as a tool to block the expression of specific genes. The use of ODNs to modify gene expression is limited by their low cellular uptake and their rapid degradation by extracellular nucleases (35). Therefore, according to our previous experience (21), ODNs were complexed with PEI to protect them and to enhance their intracellular uptake (36). Moreover, ODNs were rendered resistant to nucleases by introducing phosphorothioate linkages. A number of recent reviews have suggested guidelines in interpreting antisense studies (37). A critical step using AS relates to the evaluation of specific gene inhibition (38). For this reason, we used mutagenized ODNs with four mismatches maintaining the same base composition as the antisense molecule. This approach represents a more stringent control than sense ODN complementary to the antisense sequence or ODN composed of a random mixture of all four nucleotides (39). In our experiments, AS1 ODN directed against Zac1 significantly stimulated DNA synthesis up to 36% and 50% in AtT20 and TtT/GF cells, respectively. Recent work indicates that ODNs may block proliferation through nonantisense mechanisms, which arise from cytotoxic ODN breakdown products. If such mechanisms are influencing our measurements, the anticipated effect would be opposite of those actually obtained, and the increases in DNA synthesis seen would therefore represent an underestimate. Furthermore, exposure to the transfection vector can be toxic, as observed in this study at high concentrations. Again, such a variable would lead to an underestimate of the actual effect and reinforces the view that our results represent a conservative estimate.

Together, these considerations strongly support a genuine mode of action of AS in our experiments, as made evident by the final net increase in [3H]thymidine incorporation, and the reproducibility of our results using two AS ODNs. Moreover, we could prove that AS treatment caused a decline in Zac1 protein levels giving further credit to a causal relation among an ablation of Zac1 mRNA, decreases in Zac1 protein, and concomitant increases in [3H]thymidine incorporation. Taking into account a transfection efficiency of 70%, the percentage of DNA synthesis increase after AS treatment was high notwithstanding the heterogeneity in the quantitative ODN uptake. In this view, the ODN rhodamine incorporation experiment also offered an explanation for the incomplete suppression of the signal for Zac1 protein as documented by immunoblot analysis.

In contrast, mouse primary pituitary cells seemed essentially refractory to transfection with ODN/PEI complexes, reaching an efficiency of transfection of not more than 5% of the cells transfected (data not shown). Thus, further studies are required to substantiate the role of Zac1 in vivo, and in this view, Zac null mutant mice will be valuable tools to follow up the present findings.

In conclusion, we provide new evidence for a role of Zac1 in pituitary proliferation, using AS treatment of pituitary cell lines. Moreover, the present analysis of Zac1 expression in each anterior pituitary gland cell population is paving the way to further studies aimed at investigation of Zac1 activity in human tumor samples. The elucidation of the interaction between epigenetic and genetic lesions in pituitary cell transformation and adenoma formation will provide important clues for the evaluation of tumor stage and advancement and for improvements in the therapeutical management.


    Acknowledgments
 
We thank Rosa Buric, Yvonne Grübler, Anke Hoffmann, Ursula Hopfner, and Johanna Stalla for their excellent technical help; Dr. Penelope Largen for carefully revising the manuscript for English usage; Dr. Salvatore Raiti of the National Hormone and Pituitary Program, NIDDK (Bethesda, MD), for the gifts of FSHß, LH, TSHß, ACTH, and GH antisera; Dr. F. Talamantes, University of California (Santa Cruz, CA), for the gift of PRL antiserum; and Dr. G. L. Ferri, University of Cagliari (Cagliari, Italy) for the gift of biotinylated goat antimonkey IgGs.


    Footnotes
 
1 This work was supported by Deutsche Forschungsgemeinschaft (Sp 386/3–1). Back

2 Joint first authors. Back

Received August 27, 1998.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Mastro A, Shelton E, Hymer WC 1969 DNA synthesis in the rat anterior pituitary. J Cell Biol 43:626–629[Free Full Text]
  2. Leblond CP, Walker BE 1956 Renewal of cell populations. Physiol Rev 36:255–275[Free Full Text]
  3. Nolan LA, Kavanagh E, Lightman SL, Levy A 1998 Anterior pituitary cell population control: basal cell turnover and the effects of adrenalectomy and dexamethasone treatment. J Neuroendocrinol 10:207–215[CrossRef][Medline]
  4. Vale W, Rivier C, Brown M 1977 Regulatory peptides of the hypothalamus. Annu Rev Physiol 39:473–527[CrossRef][Medline]
  5. Renner U, Pagotto U, Arzt E, Stalla GK 1996 Autocrine and paracrine roles of polypeptide growth factors, cytokines and vasogenic substances in normal and tumorous pituitary function and growth: a review. Eur J Endocrinol 135:515–532[Abstract/Free Full Text]
  6. Shimon I, Melmed S 1997 Pituitary tumor pathogenesis. J Clin Endocrinol Metab 82:1675–1681[Free Full Text]
  7. Ambrosi B, Faglia G, Multicenter Pituitary Tumor Study Group 1991 Epidemiology of pituitary tumors. In: Faglia G, Beck-Peccoz P, Ambrosi B, Travaglini P, Spada A (eds) Pituitary Adenomas. New Trends in Basic and Clinic Research. Excerpta Medica, Amsterdam, London, New York, and Tokyo, pp 159–168
  8. Molitch ME, Russell EJ 1990 The pituitary incidentaloma. Ann Intern Med 112:925–931
  9. Saeger W 1995 Latent hyperplasias and adenomas in post-mortem pituitaries. Endocr Pathol 6:379–380
  10. Hu N, Gutsmann A, Herbert DC, Bradley A, Lee WH, Lee EYHP 1994 Heterozygous RB-1{Delta}20/+ mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance. Oncogene 9:1021–1027[Medline]
  11. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY, Nakayama K 1996 Mice lacking p27Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85:707–720[CrossRef][Medline]
  12. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares V, Hoffman ES, Ono M, Khanam D, Hayday AC, Frohmann LA, Koff A 1996 Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27Kip1. Cell 85:721–737[CrossRef][Medline]
  13. Farrell WE, Clayton RN 1998 Molecular genetics of pituitary tumours. Trends Endocrinol Metab 9:20–26[CrossRef][Medline]
  14. Spengler D, Villalba M, Hoffmann A, Pantaloni C, Houssami S, Bockaert J, Journot L 1997 Regulation of apoptosis and cell cycle arrest by ZAC1, a novel zinc finger protein expressed in the pituitary gland and the brain. EMBO J 16:2814–2825[CrossRef][Medline]
  15. Hoffmann A, Ciani E, Houssami S, Brabet P, Journot L, Spengler D 1998 Induction of type I PACAP receptor expression by the new zinc finger protein Zac1 and p53. Ann NY Acad Sci, in press
  16. Abdollahi A, Godwin AK, Miller PD, Getts LA, Schultz DC, Taguchi T, Testa JR, Hamilton TC 1997 Identification of a gene containing zinc-finger motifs based on lost expression in malignantly transformed rat ovarian surface epithelial cells. Cancer Res 57:2029–2034[Abstract/Free Full Text]
  17. Abdollahi A, Roberts D, Godwin AK, Schultz DC, Sonoda G, Testa JR, Hamilton TC 1997 Identification of a zinc-finger gene at 6q25: a chromosomal region implicated in development of many solid tumors. Oncogene 14:1973–1979[CrossRef][Medline]
  18. Pagotto U, Arzberger T, Hopfner U, Sauer J, Renner U, Newton CJ, Lange M, Uhl E, Weindl A, Stalla GK 1995 Expression and localization of endothelin-1 and endothelin receptors in human meningiomas. Evidence for a role in tumoral growth. J Clin Invest 96:2017–2025
  19. Lange M, Pagotto U, Hopfner U, Ehrenreich H, Oeckler R, Sinowatz F, Stalla GK 1994 Endothelin expression in normal human anterior pituitaries and pituitary adenomas. J Clin Endocrinol Metab 79:1864–1870[Abstract]
  20. Arzberger T, Krampfl K, Leimgruber S, Weindl A 1997 Changes of NMDA receptors subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington’s disease–an in situ hybridization study. J Neuropathol Exp Neurol 56:440–454[Medline]
  21. Boussif O, Lezoualc’h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, Behr JP 1995 A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethyenimine. Proc Natl Acad Sci USA 92:7279–7301
  22. Hunt TE 1943 Mitotic activity in the anterior hypophysis of female rats of different age groups and at different periods of the day. Endocrinology 32:334–339[Abstract/Free Full Text]
  23. Crane WAJ, Loomes RS 1967 Effect of age, sex and hormonal state on tritiated thymidine uptake by rat pituitary. Br J Cancer 21:787–792[Medline]
  24. Oishi Y, Okuda M, Takahashi H, Fujii T, Morii S 1993 Cellular proliferation in the anterior pituitary gland of normal adult rats: influences of sex, estrous cycle, and circadian change. Anat Rec 235:111–120[CrossRef][Medline]
  25. Carbajo-Perez E, Carbajo S, Orfao A, Vicente-Villardon JL, Vazquez R 1991 Circadian variation in the distribution of cells throughout the different phases of the cell cycle in the anterior pituitary gland of adult male rats as analysed by flow cytometry. J Endocrinol 129:329–333[Abstract/Free Full Text]
  26. Childs GV 1992 Structure-function correlates in the corticotropes of the anterior pituitary. Front Neuroendocrinol 13:271–317[Medline]
  27. Asa SL, Kovacs K, Hammer GD, Liu B, Roow BA, Low MJ 1992 Pituitary corticotroph hyperplasia in rats implanted with a medullary thyroid carcinoma cell line transfected with a corticotropin releasing hormone complementary deoxyribonucleic acid expression vector. Endocrinology 131:715–720[Abstract/Free Full Text]
  28. Childs GV, Rougeau D, Unabia G 1995 Corticotropin-releasing hormone and epidermal growth factor: mitogens for anterior pituitary corticotropes. Endocrinology 136:1595–1602[Abstract]
  29. Arimura A, Shioda S 1995 Pituitary adenylate cyclase activating polypetide (PACAP) and its receptors: neuroendocrine and endocrine actions. Front Neuroendocrinol 16:53–88[CrossRef][Medline]
  30. Rawlings SR, Hezareh M 1996 Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP/vasoactive intestinal polypeptide receptors: actions on the anterior pituitary gland. Endocr Rev 17:4–29[Abstract/Free Full Text]
  31. Gottschall PE, Tatsuno I, Miyata A, Arimura A 1990 Characterization and distribution of binding sites for the hypothalamic peptide, pituitary adenylate cyclase-activating polypeptide. Endocrinology 127:272–277[Abstract/Free Full Text]
  32. Gottschall PE, Tatsuno I, Arimura A 1991 Hypothalamic binding sites for pituitary adenylate cyclase activating polypeptide: characterization and molecular identification. FASEB J 5:194–199[Abstract]
  33. Vigh S, Arimura A, Gottschall PE, Kitada C, Somogyvari-Vigh A, Childs GV 1993 Cytochemical characterization of anterior pituitary target cells for the neuropeptide, pituitary adenylate cyclase activating polypeptide (PACAP), using biotinylated ligands. Peptides 14:59–65[CrossRef][Medline]
  34. Inoue K, Matsumoto H, Koyama C, Shibata K, Nakazato Y, Ito A 1992 Establishment of a folliculo-stellate-like cell line from a murine thyrotropic pituitary tumor. Endocrinology 131:3110–3116[Abstract/Free Full Text]
  35. Wagner RW, Flanagan MW 1997 Antisense technology and prospects for therapy of viral infections and cancer. Mol Med Today 3:31–38[CrossRef][Medline]
  36. Boussif O, Zanta MA, Behr JP 1996 Optimized galenics improve in vitro gene transfer with cationic molecules up to 1000-fold. Gene Ther 3:1074–1080[Medline]
  37. Branch AD 1998 A good antisense molecule is hard to find. Trends Biochem Sci 23:45–50[CrossRef][Medline]
  38. Wahlestedt C 1994 Antisense oligonucleotide strategies in neuropharmacology. Trends Pharmacol Sci 15:42–46[CrossRef][Medline]
  39. Wagner RW 1994 Gene inhibition using antisense oligodeoxynucleotides. Nature 372:333–335[CrossRef][Medline]



This article has been cited by other articles:


Home page
Cancer Res.Home page
T. Barz, A. Hoffmann, M. Panhuysen, and D. Spengler
Peroxisome Proliferator-Activated Receptor {gamma} Is a Zac Target Gene Mediating Zac Antiproliferation
Cancer Res., December 15, 2006; 66(24): 11975 - 11982.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
A. Hoffmann, T. Barz, and D. Spengler
Multitasking C2H2 Zinc Fingers Link Zac DNA Binding to Coordinated Regulation of p300-Histone Acetyltransferase Activity.
Mol. Cell. Biol., July 1, 2006; 26(14): 5544 - 5557.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Theodoropoulou, J. Zhang, S. Laupheimer, M. Paez-Pereda, C. Erneux, T. Florio, U. Pagotto, and G. K. Stalla
Octreotide, a Somatostatin Analogue, Mediates Its Antiproliferative Action in Pituitary Tumor Cells by Altering Phosphatidylinositol 3-Kinase Signaling and Inducing Zac1 Expression
Cancer Res., February 1, 2006; 66(3): 1576 - 1582.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Contestabile, T. Fila, R. Bartesaghi, and E. Ciani
Cyclic AMP-mediated Regulation of Transcription Factor Lot1 Expression in Cerebellar Granule Cells
J. Biol. Chem., September 30, 2005; 280(39): 33541 - 33551.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
E. Basyuk, V. Coulon, A. Le Digarcher, M. Coisy-Quivy, J.-P. Moles, A. Gandarillas, and L. Journot
The Candidate Tumor Suppressor Gene ZAC Is Involved in Keratinocyte Differentiation and Its Expression Is Lost in Basal Cell Carcinomas
Mol. Cancer Res., September 1, 2005; 3(9): 483 - 492.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
M. O. Velardez, A. H. Poliandri, J. P. Cabilla, C. C. A. Bodo, L. I. Machiavelli, and B. H. Duvilanski
Long-Term Treatment of Anterior Pituitary Cells with Nitric Oxide Induces Programmed Cell Death
Endocrinology, April 1, 2004; 145(4): 2064 - 2070.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
A. Hoffmann, E. Ciani, J. Boeckardt, F. Holsboer, L. Journot, and D. Spengler
Transcriptional Activities of the Zinc Finger Protein Zac Are Differentially Controlled by DNA Binding
Mol. Cell. Biol., February 1, 2003; 23(3): 988 - 1003.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
U. Pagotto, T. Arzberger, M. Theodoropoulou, Y. Grübler, C. Pantaloni, W. Saeger, M. Losa, L. Journot, G. K. Stalla, and D. Spengler
The Expression of the Antiproliferative Gene ZAC Is Lost or Highly Reduced in Nonfunctioning Pituitary Adenomas
Cancer Res., December 1, 2000; 60(24): 6794 - 6799.
[Abstract] [Full Text]


Home page
Hum Mol GenetHome page
M. Kamiya, H. Judson, Y. Okazaki, M. Kusakabe, M. Muramatsu, S. Takada, N. Takagi, T. Arima, N. Wake, K. Kamimura, et al.
The cell cycle control gene ZAC/PLAGL1 is imprinted--a strong candidate gene for transient neonatal diabetes
Hum. Mol. Genet., February 12, 2000; 9(3): 453 - 460.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
Y. Maebayashi, Y. Shigeyoshi, T. Takumi, and H. Okamura
A Putative Transcription Factor with Seven Zinc-Finger Motifs Identified in the Developing Suprachiasmatic Nucleus by the Differential Display PCR Method
J. Neurosci., November 15, 1999; 19(22): 10176 - 10183.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pagotto, U.
Right arrow Articles by Stalla, G. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pagotto, U.
Right arrow Articles by Stalla, G. K.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals